Live
FierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamPharmaVoiceCompetition is brewing between ADCs and bispecificsPromega BlogThe Hidden Switch That Controls Lysosome FunctionFierceBiotechCardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPOFierceBiotechCaribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3CellDNA repair drives cisplatin-induced neuronal deathCellLong-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humansCellPersistent and transient senescent cells contribute to brain-barrier developmentCellContinuous modeling of primate embryogenesis from totipotency to early organogenesisCellRNA structure programs endogenous ADAR for precise and efficient editing
BioWorld 27 nov. 2025

Blossomhill Therapeutics describes new macrocyclic compounds

Blossomhill Therapeutics describes new macrocyclic compounds

Original
Contenu indisponible. Consultez la source originale.